Teladoc Health, Inc. (TDOC)

Teladoc Health’s second fiscal quarter of 2026, reported July 29 and based on preliminary results, saw EPS of -$0.21 beat the -$0.24 estimate by about 13% even as revenue fell 4% to about $606.9 million and missed the about $615.4 million consensus by roughly 1%. Revenue was concentrated in the U.S., the largest segment at about $491.5 million, which declined 6%, while Other climbed 25% to about $129.2 million and International rose 17% to about $122.3 million. Gross margin held near 84% and operating margin was about -8%, with operating loss at about $50.1 million and net loss at about $38.9 million, wider than about $32.7 million a year ago. EPS was also down from -$0.19 a year earlier. Operating cash flow came in at about $64.7 million. Next-period consensus calls for EPS of -$0.18 on revenue of $629.2 million.